Shock Therapy Shows Promise for Mysterious Regression in Down Syndrome

For families of young people with Down syndrome, few experiences are as devastating as watching a teenager or young adult suddenly lose skills they had spent years acquiring. Speech fades, motivation collapses, and the person seems to withdraw behind a wall of silence and stillness. This bewildering condition, known as Down syndrome regression disorder, has long puzzled clinicians, and its treatment options have remained frustratingly limited. Now, a new study published in the Journal of Autism and Developmental Disorders offers the most comprehensive evidence to date that electroconvulsive therapy, one of psychiatry’s oldest and most misunderstood treatments, may dramatically reduce the catatonic symptoms that often accompany this regression.

The research team, led by Seri Lim and Joshua Ryan Smith of Vanderbilt University Medical Center, along with collaborators at Massachusetts General Hospital, Harvard Medical School, and the University of Queensland, combined a case series of five patients treated at Vanderbilt with a systematic review of the international literature. By pooling participant-level data rather than relying on study-level summaries, the investigators assembled a cohort of 27 individuals with Down syndrome regression disorder and co-occurring catatonia who had received electroconvulsive therapy. According to the authors, this represents the largest analysis conducted so far on the use of the treatment in this population.

Down syndrome itself is the most common genetic cause of intellectual disability worldwide, arising in roughly one in 800 to 1,000 live births, most often through trisomy of chromosome 21. More than 214,000 people with Down syndrome live in the United States alone. Down syndrome regression disorder, previously called Down syndrome disintegrative disorder, is a potentially life-threatening complication marked by an acute or subacute loss of previously acquired skills, cognitive decline, affective instability, and language regression. Patients may develop new-onset insomnia, psychomotor slowing, mutism, and catatonia. The underlying causes remain poorly understood, though researchers have hypothesized roles for autoimmune dysregulation, psychosocial stressors, and co-morbid psychiatric illness.

Catatonia, the condition at the heart of the new analysis, is a treatable psychomotor syndrome characterized by distinct physical examination findings such as staring, grimacing, rigidity, and mutism. It can occur across the neurodivergent spectrum and throughout the lifespan, and it carries substantial morbidity and mortality, particularly among children and adolescents. Individuals with neurodevelopmental disorders face an elevated risk of delayed diagnosis, and their catatonia may present unusually, with loss of previously acquired skills and communicative abilities that mirror the broader regression seen in Down syndrome regression disorder. Some researchers have even questioned whether catatonia is a core component of the regression disorder itself, or whether the condition belongs on the catatonia spectrum.

To quantify the effect of electroconvulsive therapy, the team relied on the Bush-Francis Catatonia Rating Scale, a 23-item clinical instrument that grades the severity of each catatonic sign, with a maximum possible score of 69. Across the combined dataset, 17 pre-treatment and 15 post-treatment scores were available from 18 patients across seven sites or studies. The mean score before treatment was 17.40, falling to 4.40 afterward. A generalized estimating equations analysis, which accounts for the clustering of patients within the same study, found a statistically significant reduction of 13.00 points, with a 95 percent confidence interval spanning from 17.70 down to 8.18 and a p-value below 0.001. In plain terms, the treatment was associated with a substantial and statistically robust easing of catatonic symptoms.

The clinical picture of the patients underscores how difficult these cases are. The 27 patients, whose average age was 20.7 years, had collectively failed dozens of medication trials before turning to electroconvulsive therapy, with a mean of 2.4 failed psychiatric medications per patient. Lorazepam, a benzodiazepine and standard first-line agent for catatonia, had been tried in two-thirds of the cohort. Selective serotonin reuptake inhibitors such as sertraline and fluoxetine, antipsychotics such as quetiapine and aripiprazole, mood stabilizers, anticonvulsants, and even the NMDA receptor antagonist memantine had all been deployed with limited success. Medical and psychiatric comorbidities were common, including hypothyroidism in more than a fifth of patients, celiac disease, autoimmune encephalitis, major depressive disorder, and autism spectrum disorder.

The technical details of the treatment at Vanderbilt offer a rare window into how electroconvulsive therapy is actually delivered in this population. All five Vanderbilt patients received bitemporal electrode placement with brief-pulse stimulation, undergoing 171 treatments in total. Anesthesia was induced with methohexital at a mean dose of 68.4 milligrams, with succinylcholine providing muscle relaxation. Electroencephalographic seizure duration averaged 60.9 seconds, and propofol was used to terminate prolonged seizures, defined as those exceeding two minutes, in 19 percent of sessions. Notably, in about 16 percent of treatments, intramuscular ketamine was required to establish intravenous access because agitation or distress prevented conventional placement, a maneuver the authors report as the first described in this population. Despite the intensity of the treatment course, no severe adverse events were documented, although all five patients had difficulty verbalizing subjective side effects because of their intellectual disability.

The findings arrive with important caveats. The sample remains small, the data were collected retrospectively, and the analysis carries an inherent bias toward positive outcomes: patients unlikely to continue receiving dozens of electroconvulsive sessions unless some benefit was observed. Reporting of treatment parameters and rating scales was inconsistent across the studies included in the systematic review, and many patients received concurrent therapies, including intravenous immunoglobulin in a third of cases, making it impossible to isolate the specific contribution of the electrical stimulation. The authors also note that eight patients in the cohort were under 18, an age group whose access to electroconvulsive therapy is restricted by state-dependent legislation in the United States, and that stigma, limited education, and provider shortages limit availability worldwide.

Even so, the study marks a turning point for a condition that has lacked any evidence-based treatment algorithm. The authors recommend that future research examine electroconvulsive therapy for catatonia in Down syndrome regression disorder prospectively, with standardized reporting of electrode placement, pulse width, seizure duration, acute and maintenance treatment schedules, and cognitive outcomes. They also call for improved screening, including telemedicine-based catatonia assessments, to speed diagnosis in a population where symptoms are easily mistaken for the regression itself. Given the significant improvement in both regression and catatonic symptoms observed, the researchers suggest that clinicians should consider electroconvulsive therapy earlier in the disease course rather than as a last resort after years of failed medication trials.

For a condition that can strip away speech, movement, and independence in a matter of months, the message of this study is quietly radical: a treatment often portrayed as barbaric may, carefully administered, give young people with Down syndrome their lives back. The evidence base is still thin, built on 27 patients and seven research sites, but the signal is strong, the treatment was well tolerated, and the alternative for many families is watching a child disappear into unresponsive silence. As the authors conclude, more rigorous research is needed, but the era of assuming nothing can be done for regression in Down syndrome may finally be coming to an end.

Subject of Research: Electroconvulsive therapy for catatonia in Down syndrome regression disorder

Article Title: Use of Electroconvulsive Therapy for Catatonia in Down Syndrome Regression Disorder: A Systematic Review, Case Series, and Analysis

Article References: Lim, S., Kang, K., Oey, E., Santoro, S., Franklin, C., Luccarelli, J., Tamargo, R., Hamilton, C., Marler, S., Adegoke, T., Wilson, J. E., & Smith, J. R. (2026). Use of Electroconvulsive Therapy for Catatonia in Down Syndrome Regression Disorder: A Systematic Review, Case Series, and Analysis. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-026-07500-3

Image Credits: AI Generated

DOI: 10.1007/s10803-026-07500-3

Keywords: Down syndrome, Down syndrome regression disorder, catatonia, electroconvulsive therapy, Bush-Francis Catatonia Rating Scale, systematic review, case series, psychiatry, neurodevelopmental disorders, regression, ketamine, Vanderbilt University Medical Center